Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.

"Declarations Ethics approval and consent to participate: Not applicable.Consent for publication: Not applicable.Author contributions:Yohei Kubota: Investigation; Writing – original draft.Kohei Shitara: Supervision; Writing – review & editing.Funding: The authors received no financial support for the research, authorship, and/or publication of this article.Competing interests: YK reports receiving research funding from Astellas Pharma. KS reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, and Janssen; receiving honoraria (lecture fee) from Takeda and Bristol-Myers Squibb; and receiving research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, MSD, Medi Science, Eisai and Amgen, outside the submitted work.Availability of data and materials: Not applicable. Competing interests: YK reports receiving research funding from Astellas Pharma. KS reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, and Janssen; receiving honoraria (lecture fee) from Takeda and Bristol-Myers Squibb; and receiving research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, MSD, Medi Science, Eisai and Amgen, outside the submitted work."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."